Roche Aims to Capitalize on Obesity-Drug Market as It Seeks Recovery Amid Sector Turmoil

  • 📰 IrishTimes
  • ⏱ Reading Time:
  • 20 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 35%
  • Publisher: 98%

Business And Finance Noticias

Roche,Obesity Drugs,Carmot Acquisition

Swiss pharmaceutical giant Roche is making a major move in the obesity-drugs market by acquiring Carmot for up to $3.1 billion. The company hopes this acquisition will help it regain a leading position in an area expected to grow to $200 billion by 2031, following a period of decline.

Investors who have been enduring a turbulent ride since Malin's flotation in March 2015, now face a potential end to the uncertainty as Roche eyes a recovery in the obesity-drugs market. Roche, previously underperforming and grappling with declining sales of its COVID-19 test kits and drug candidate failures, has made a significant move this year by acquiring Carmot for up to $3.1 billion.

This acquisition comes as the obesity-drugs market is projected to grow significantly, reaching an estimated $200 billion by 2031. The wider pharmaceutical sector, meanwhile, has been dealing with the repercussions of Donald Trump's re-election and the proposed appointment of an anti-vaccine activist as his health secretary, which has led to a further downturn in stock prices

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 3. in CO
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

Colombia Últimas Noticias, Colombia Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Malin Corporation Shares Jump 37% on Roche Acquisition of PoseidaMalin Corporation, a Dublin-based life sciences investment firm, experienced a significant rise in its share price following the news that Roche, a Swiss pharmaceuticals giant, has agreed to acquire Poseida, a Nasdaq-listed biopharma company in which Malin holds a 12% stake, for up to $1.5 billion.
Fuente: IrishTimes - 🏆 3. / 98 Leer más »